Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update. Read full release: ir.lisata.com/news-releases/…

Today on #ClinicalTrialsDay, we honor those who make medical advances possible: trial participants, researchers, and regulatory professionals. At Lisata, our trials aim to advance treatments for cancer and other serious conditions. Learn more: lisata.com/active-clinica…

In today’s Clinical Leader #ClinicalTrialsDay feature, Dr. Kristen Buck, Lisata’s CMO, discusses how strategic collaborations have helped the Company overcome funding challenges to advance certepetide across multiple solid tumors. Read more: bit.ly/3H1watg

On #NationalCancerSurvivorsDay, we honor cancer survivors' strength and resilience. At Lisata, we're committed to developing innovative therapies like certepetide that may improve treatment outcomes for patients with advanced solid tumors. #LisataTherapeutics

During #MensHealthWeek, we spotlight our work targeting solid tumors that disproportionately impact men. Certepetide aims to enhance drug penetration in tumors, offering hope through our innovative CendR Platform® technology. #LisataTherapeutics #CancerResearch

Lisata Therapeutics to Present at the 2025 BIO International Convention Read the press release for details: ir.lisata.com/news-releases/… #LisataTherapeutics #Oncology

Lisata is heading to Biotechnology Innovation Organization’s #BIO2025 in Boston! Our CEO David Mazzo presents on June 17 at 11:15 am. Join us as we connect with the global biotech community. #LisataTherapeutics #Biotechnology

Lisata Therapeutics and GATC HEALTH Expand Relationship to Advance AI-Driven Drug Discovery and Development Read the press release for details: ir.lisata.com/news-releases/… #LisataTherapeutics

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer Read the press release for details: ir.lisata.com/news-releases/…

Dr. Andrew Dean will present @ESMO – Eur. Oncology Gastrointestinal Cancers Congress in Barcelona about preliminary ASCEND trial results on certepetide in pancreatic cancer treatment. #LisataTherapeutics #ESMOGICongress #CancerInnovation

Lisata Therapeutics Strengthens Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide Read the release for details: ir.lisata.com/news-releases/… #LisataTherapeutics

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update Read the press release for details: ir.lisata.com/news-releases/… #LisataTherapeutics

On #GlioblastomaAwarenessDay, we honor the strength of patients, survivors & caregivers affected by glioblastoma (#GBM) and other brain cancers. At Lisata, we're committed to improving treatment for advanced solid tumors, including glioblastoma multiforme. #LisataTherapeutics

On the latest WTR Healthcare Spotlight podcast, Tim Gerdeman and Robert Sassoon were joined by Lisata Therapeutics, Inc. (NASDAQ: LSTA) CEO David J. Mazzo, Ph.D., PhD, and CMO Kristen K. Buck MD, to discuss Certepetide—Lisata’s novel tumor-penetrating therapy—and encouraging preliminary Phase

Lisata's leadership team recently discussed its novel tumor-penetrating therapy, certepetide, and the preliminary Ph 2b results in mPDAC on Water Tower Research LLC podcast. Key topics: lead program insights, partnerships, & what’s next Listen: pod.link/1693448305 #LisataTherapeutics

On Thursday, August 7, we will announce our Second Quarter 2025 Financial Results after the close of trading and will host a conference call at 4:30 p.m. ET. To participate on the call, please register here: ir.lisata.com/news-releases/…

Join us today for our Second Quarter 2025 Financial Results and Business Update Conference Call at 4:30 p.m. ET.  To participate on the call, please register here: register-conf.media-server.com/register/BI554… Tune in to the webcast here: edge.media-server.com/mmc/p/5ranib5w/

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update. Read full release: ir.lisata.com/news-releases/…

#ICYMI: Lisata secured a new composition of matter patent for certepetide, extending IP protection through March 2040. The patent covers chemical structure, manufacturing, and cancer treatment applications - the strongest form of IP protection. Read more: bit.ly/4o33GQQ

#ICYMI: Lisata expanded its alliance with GATC Health to advance their AI-driven MAT™ platform. The partnership accelerates development of an AI-discovered non-opioid treatment for opioid use disorder, with Phase 1 trials targeted for early 2026. Read: bit.ly/3IHQoZR